Kimmtrak, Tivdak to require prior authorization for most members

For dates of service on or after May 23, 2022, we’re adding prior authorization requirements for the following drugs covered under the medical benefit:

• Kimmtrak^® (tebentafusp-tebn), HCPCS code J3490, J3590, J9999, C9399
• Tivdak^® (tisotumab vedotin-tftv), HCPCS code J9273

Prior authorization requirements apply when these drugs are administered in outpatient settings for:

• Blue Cross Blue Shield of Michigan commercial members who have coverage through fully insured groups and who have individual coverage

Exceptions: These requirements don’t apply to Blue Cross members who have coverage through the Blue Cross and Blue Shield Federal Employee Program^®, UAW Retiree Medical Benefits Trust non-Medicare members or other Blue Cross commercial members with coverage through self-funded groups.

• Medicare Plus Blue℠ members
• Blue Care Network commercial members
• BCN Advantage℠ members

Submit authorization requests to AIM Specialty Health^® using one of the following methods:

• Through the AIM ProviderPortal**
• By calling the AIM Contact Center at 1-844-377-1278

For information about registering for and accessing the AIM ProviderPortal, refer to the Frequently asked questions page on the AIM website.**

Authorization isn’t a guarantee of payment. As always, health care practitioners need to verify eligibility and benefits for members. For additional information on requirements related to drugs covered under the medical benefit, see:

• Blue Cross commercial and BCN commercial:
• Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members
• Blue Cross and BCN utilization management medical drug list
• Medicare Advantage: Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members

We’ll update the appropriate drug lists to reflect the information in this message prior to the effective date.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.